↓ Skip to main content

Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation

Overview of attention for article published in Journal of Biomedical Science, August 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news
2 news outlets
twitter
4 X users
patent
2 patents
facebook
1 Facebook page
reddit
2 Redditors
video
1 YouTube creator

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation
Published in
Journal of Biomedical Science, August 2014
DOI 10.1186/s12929-014-0074-2
Pubmed ID
Authors

Rita U Ostrovskaya, Yulia V Vakhitova, Uliyana Sh Kuzmina, Milyausha Kh Salimgareeva, Liana F Zainullina, Tatiana A Gudasheva, Vener A Vakhitov, Sergey B Seredenin

Abstract

BackgroundNoopept (N-phenyl-acetyl-L-prolylglycine ethyl ester) was constructed as a dipeptide analog of the standard cognition enhancer, piracetam. Our previous experiments have demonstrated the cognition restoring effect of noopept in several animal models of Alzheimer disease (AD). Noopept was also shown to prevent ionic disbalance, excitotoxicity, free radicals and pro-inflammatory cytokines accumulation, and neurotrophine deficit typical for different kinds of brain damages, including AD. In this study, we investigated the neuroprotective action of noopept on cellular model of AD, Aß25¿35-induced toxicity in PC12 cells and revealed the underlying mechanisms.ResultsThe neuroprotective effect of noopept (added to the medium at 10 ¿M concentration, 72 hours before ¿ß25¿35) was studied on ¿ß25¿35-induced injury (5 ¿M for 24 h) in PC12 cells. The ability of drug to protect the impairments of cell viability, calcium homeostasis, ROS level, mitochondrial function, tau phosphorylation and neurite outgrowth caused by ¿ß25¿35 were evaluated.Following the exposure of PC12 cells to ¿ß25¿35 an increase of the level of ROS, intracellular calcium, and tau phosphorylation at Ser396 were observed; these changes were accompanied by a decrease in cell viability and an increase of apoptosis. Noopept treatment before the amyloid-beta exposure improved PC12 cells viability, reduced the number of early and late apoptotic cells, the levels of intracellular reactive oxygen species and calcium and enhanced the mitochondrial membrane potential. In addition, pretreatment of PC12 cell with noopept significantly attenuated tau hyperphosphorylation at Ser396 and ameliorated the alterations of neurite outgrowth evoked by ¿ß25¿35.ConclusionsTaken together, these data provide evidence that novel cognitive enhancer noopept protects PC12 cell against deleterious actions of Aß through inhibiting the oxidative damage and calcium overload as well as suppressing the mitochondrial apoptotic pathway. Moreover, neuroprotective properties of noopept likely include its ability to decrease tau phosphorylation and to restore the altered morphology of PC12 cells. Therefore, this nootropic dipeptide is able to positively affect not only common pathogenic pathways but also disease-specific mechanisms underlying Aß-related pathology.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Estonia 1 2%
Unknown 49 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 16 32%
Student > Ph. D. Student 11 22%
Researcher 8 16%
Student > Master 5 10%
Lecturer > Senior Lecturer 1 2%
Other 3 6%
Unknown 6 12%
Readers by discipline Count As %
Agricultural and Biological Sciences 9 18%
Neuroscience 7 14%
Biochemistry, Genetics and Molecular Biology 5 10%
Chemistry 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Other 12 24%
Unknown 10 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 December 2023.
All research outputs
#1,376,486
of 25,550,333 outputs
Outputs from Journal of Biomedical Science
#55
of 1,108 outputs
Outputs of similar age
#13,511
of 241,889 outputs
Outputs of similar age from Journal of Biomedical Science
#2
of 15 outputs
Altmetric has tracked 25,550,333 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,108 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,889 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.